-
公开(公告)号:US5461065A
公开(公告)日:1995-10-24
申请号:US138643
申请日:1993-10-15
IPC分类号: C07D333/56 , A61K31/38 , A61K31/381 , A61K31/40 , A61K31/4025 , A61K31/445 , A61K31/4453 , A61K31/4535 , A61P13/02 , A61P15/00 , A61P15/02
CPC分类号: A61K31/381 , A61K31/38 , A61K31/40 , A61K31/445 , A61K31/4535
摘要: A method of inhibiting endometriosis comprising administering to a human in need of treatment an effective amount of a compound having the formula ##STR1## Wherein R.sup.1 and R.sup.3 are independently hydrogen, --CH.sub.3, ##STR2## wherein Ar is optionally substituted phenyl;R.sup.2 is selected from the group consisting of pyrrolidine and piperidino; or a pharmaceutically acceptable salt of solvate thereof.
摘要翻译: 抑制子宫内膜异位症的方法包括对需要治疗的人施用有效量的具有下式的化合物(Ⅰ),其中R1和R3独立地是氢,-CH3,其中Ar是任选取代的苯基; R2选自吡咯烷和哌啶子基; 或其药学上可接受的盐的溶剂合物。
-
公开(公告)号:US5457116A
公开(公告)日:1995-10-10
申请号:US138642
申请日:1993-10-15
IPC分类号: C07D333/56 , A61K31/38 , A61K31/381 , A61K31/40 , A61K31/4025 , A61K31/445 , A61K31/4453 , A61K31/4535 , A61P13/02 , A61P15/00 , A61P15/02
CPC分类号: A61K31/38 , A61K31/40 , A61K31/445
摘要: A method of inhibiting uterine fibrosis comprising administering to a human or other mammal in need of treatment an effective amount of a compound having the formula ##STR1## Wherein R.sup.1 and R.sup.3 are independently hydrogen, ##STR2## wherein Ar is optionally substituted phenyl; wherein R.sup.2 is selected from the group consisting of pyrrolidino and piperidino, a pharmaceutically acceptable salt or solvate thereof.
摘要翻译: 一种抑制子宫纤维化的方法,包括对需要治疗的人或其他哺乳动物施用有效量的具有式(I)的化合物,其中R1和R3独立地是氢,其中Ar是任选取代的苯基 ; 其中R2选自吡咯烷子基和哌啶子基,其药学上可接受的盐或溶剂合物。
-
公开(公告)号:US5693656A
公开(公告)日:1997-12-02
申请号:US422387
申请日:1995-04-14
IPC分类号: C07D333/56 , A61K31/38 , A61K31/381 , A61K31/40 , A61K31/4025 , A61K31/445 , A61K31/4453 , A61K31/4535 , A61P13/02 , A61P15/00 , A61P15/02
CPC分类号: A61K31/381 , A61K31/38 , A61K31/40 , A61K31/445 , A61K31/4535
摘要: A method of inhibiting endometriosis comprising administering to a human in need of treatment an effective amount of a compound having the formula ##STR1## Wherein R.sup.1 and R.sup.3 are independently hydrogen, --CH.sub.3, ##STR2## wherein Ar is optionally substituted phenyl; R.sup.2 is selected from the group consisting of pyrrolidine and piperidino; or a pharmaceutically acceptable salt of solvate thereof.
摘要翻译: 抑制子宫内膜异位症的方法包括对需要治疗的人施用有效量的具有下式的化合物(Ⅰ),其中R1和R3独立地是氢,-CH3,其中Ar是任选取代的苯基; R2选自吡咯烷和哌啶子基; 或其药学上可接受的盐的溶剂合物。
-
-